Codagenix pursues RSV vaccine development amid unexpected challenges

Codagenix faces a late 2024 data readout following enrollment challenges in its paediatric RSV vaccine Phase I study.

Aug 30, 2023 - 20:00

Codagenix pursues RSV vaccine development amid unexpected challenges

Codagenix faces a late 2024 data readout following enrollment challenges in its paediatric RSV vaccine Phase I study.

Read the original article

Tags:

Previous Article

FDA shuns Outlook Therapeutics with wet AMD drug BLA rejection

Roche wins first approval for subcutaneous Tecentriq

What's Your Reaction?

0

Like

0

Dislike

0

Love

0

Funny

0

Angry

0

Sad

0

Wow

Related Posts

AbbVie looks to add an eighth indication for JAK inhibitor Rinvoq

AbbVie looks to add an eighth indication for JAK inhibi...

Jul 16, 2024

STAT+: Drug firms test medicines to halt Alzheimer’s before symptoms appear

STAT+: Drug firms test medicines to halt Alzheimer’s be...

Aug 31, 2023

STAT+: Sanofi CEO defends company’s move to abandon profit guidance and boost research

STAT+: Sanofi CEO defends company’s move to abandon pro...

Nov 9, 2023